These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
61 related articles for article (PubMed ID: 8852330)
1. Advances with phospholipid signalling as a target for anticancer drug development. Powis G; Berggren M; Gallegos A; Frew T; Hill S; Kozikowski A; Bonjouklian R; Zalkow L; Abraham R; Ashendel C Acta Biochim Pol; 1995; 42(4):395-403. PubMed ID: 8852330 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of the signalling enzyme phosphatidylinositol-3-kinase by antitumor ether lipid analogues. Berggren MI; Gallegos A; Dressler LA; Modest EJ; Powis G Cancer Res; 1993 Sep; 53(18):4297-302. PubMed ID: 8395981 [TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. Schultz RM; Merriman RL; Andis SL; Bonjouklian R; Grindey GB; Rutherford PG; Gallegos A; Massey K; Powis G Anticancer Res; 1995; 15(4):1135-9. PubMed ID: 7653991 [TBL] [Abstract][Full Text] [Related]
4. Novel quinone antiproliferative inhibitors of phosphatidylinositol-3-kinase. Frew T; Powis G; Berggren M; Gallegos A; Abraham RT; Ashendel CL; Zalkow LH; Hudson C; Gruszecka-Kowalik E; Burgess EM Anticancer Drug Des; 1995 Jun; 10(4):347-59. PubMed ID: 7786399 [TBL] [Abstract][Full Text] [Related]
5. Drugs active against growth factor and oncogene phosphatidylinositol signalling pathways. Powis G Semin Cancer Biol; 1992 Dec; 3(6):343-50. PubMed ID: 1286155 [TBL] [Abstract][Full Text] [Related]
6. Studies on the mechanism of phosphatidylinositol 3-kinase inhibition by wortmannin and related analogs. Norman BH; Shih C; Toth JE; Ray JE; Dodge JA; Johnson DW; Rutherford PG; Schultz RM; Worzalla JF; Vlahos CJ J Med Chem; 1996 Mar; 39(5):1106-11. PubMed ID: 8676346 [TBL] [Abstract][Full Text] [Related]
7. Wortmannin inhibits the growth of mammary tumors despite the existence of a novel wortmannin-insensitive phosphatidylinositol-3-kinase. Lemke LE; Paine-Murrieta GD; Taylor CW; Powis G Cancer Chemother Pharmacol; 1999; 44(6):491-7. PubMed ID: 10550570 [TBL] [Abstract][Full Text] [Related]
8. Characterization of a soluble adrenal phosphatidylinositol 4-kinase reveals wortmannin sensitivity of type III phosphatidylinositol kinases. Downing GJ; Kim S; Nakanishi S; Catt KJ; Balla T Biochemistry; 1996 Mar; 35(11):3587-94. PubMed ID: 8639510 [TBL] [Abstract][Full Text] [Related]
9. Fluorinated cyclitols as useful biological probes of phosphatidylinositol metabolism. Schedler DJ; Baker DC Carbohydr Res; 2004 Jun; 339(9):1585-95. PubMed ID: 15183732 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and in vitro evaluation of new wortmannin esters: potent inhibitors of phosphatidylinositol 3-kinase. Creemer LC; Kirst HA; Vlahos CJ; Schultz RM J Med Chem; 1996 Dec; 39(25):5021-4. PubMed ID: 8960564 [TBL] [Abstract][Full Text] [Related]
12. Wortmannin, a phosphoinositide 3-kinase inhibitor, selectively enhances cytotoxicity of receptor-directed-toxin chimeras in vitro and in vivo. Davol PA; Bizuneh A; Frackelton AR Anticancer Res; 1999; 19(3A):1705-13. PubMed ID: 10470104 [TBL] [Abstract][Full Text] [Related]
13. Pegylated wortmannin and 17-hydroxywortmannin conjugates as phosphoinositide 3-kinase inhibitors active in human tumor xenograft models. Zhu T; Gu J; Yu K; Lucas J; Cai P; Tsao R; Gong Y; Li F; Chaudhary I; Desai P; Ruppen M; Fawzi M; Gibbons J; Ayral-Kaloustian S; Skotnicki J; Mansour T; Zask A J Med Chem; 2006 Feb; 49(4):1373-8. PubMed ID: 16480272 [TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors. Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602 [TBL] [Abstract][Full Text] [Related]
15. Inhibitors of phosphatidylinositol signalling as antiproliferative agents. Powis G; Phil D Cancer Metastasis Rev; 1994 Mar; 13(1):91-103. PubMed ID: 8143348 [TBL] [Abstract][Full Text] [Related]
16. Substrate properties of analogs of myo-inositol. Moyer JD; Reizes O; Ahir S; Jiang C; Malinowski N; Baker DC Mol Pharmacol; 1988 Jun; 33(6):683-9. PubMed ID: 2837638 [TBL] [Abstract][Full Text] [Related]
17. Inositol hexaphosphate inhibits cell transformation and activator protein 1 activation by targeting phosphatidylinositol-3' kinase. Huang C; Ma WY; Hecht SS; Dong Z Cancer Res; 1997 Jul; 57(14):2873-8. PubMed ID: 9230193 [TBL] [Abstract][Full Text] [Related]
18. Role of phosphatidylinositol 3-OH-kinase activity in the inhibition of apoptosis in haemopoietic cells: phosphatidylinositol 3-OH-kinase inhibitors reveal a difference in signalling between interleukin-3 and granulocyte-macrophage colony stimulating factor. Scheid MP; Lauener RW; Duronio V Biochem J; 1995 Nov; 312 ( Pt 1)(Pt 1):159-62. PubMed ID: 7492306 [TBL] [Abstract][Full Text] [Related]
19. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Faivre S; Djelloul S; Raymond E Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796 [TBL] [Abstract][Full Text] [Related]
20. A multiwell assay for inhibitors of phosphatidylinositol-3-kinase and the identification of natural product inhibitors. Frew T; Powis G; Berggren M; Abraham RT; Ashendel CL; Zalkow LH; Hudson C; Qazia S; Gruszecka-Kowalik E; Merriman R Anticancer Res; 1994; 14(6B):2425-8. PubMed ID: 7872663 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]